Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Biodesix, Inc. (BDSX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.26000.0000 (0.00%)
At close: 04:00PM EDT
1.1900 -0.07 (-5.56%)
After hours: 07:04PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.2600
Open1.2500
Bid1.2200 x 800
Ask1.3100 x 800
Day's Range1.2400 - 1.3700
52 Week Range1.2250 - 8.7500
Volume50,530
Avg. Volume157,696
Market Cap34.054M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3640
Earnings DateMar 14, 2022 - Mar 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • Business Wire

    Biodesix to Participate in Two Upcoming Investor Conferences in September

    BOULDER, Colo., September 06, 2022--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences:

  • Business Wire

    Biodesix Named a Top 100 Healthcare Technology Company of 2022

    BOULDER, Colo., August 09, 2022--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has been recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022. The company develops and commercializes blood-based diagnostic tests designed to address important unmet needs in healthcare, by combining multi-omics through the power of artificial intelligence. Biodesix offers five non-invasiv

  • Motley Fool

    Biodesix, Inc. (BDSX) Q2 2022 Earnings Call Transcript

    At this time, I would like to welcome everyone to the Biodesix's second quarter 2022 earnings conference call. Thank you for joining us today for a discussion of Biodesix's second quarter 2022 business highlights and financial results. Leading the call today will be Scott Hutton, chief executive officer.

Advertisement
Advertisement